Jeffrey Herz, Ph.D.
President and Chief Executive Officer
Dr. Jeffrey Herz, Ph.D, is the founder of Algomedix and serves as President and CEO. He has more than twenty-five years of drug development and management experience in the biotechnology and pharmaceutical industry. His areas of expertise span discovery research, pharmaceutical product development and clinical trials. Dr. Herz established the TRPA1 drug discovery and development program for chronic pain at Algomedix and has led development efforts for this potential first-in-class non-opioid analgesic.
Prior to founding Algomedix, Dr. Herz was the founding scientist at Omeros and led discovery and pharmaceutical research programs for 15 years in multiple therapeutic areas. His management responsibilities included drug discovery, preclinical research, pharmacology, and clinical support, as well as patents. His efforts resulted in three products which progressed from inception to late-stage clinical trials, and an FDA approved product on the market. Dr. Herz previously served as founder and President of Applied Receptor Sciences. He has held positions of increasing responsibility during his work with multiple biotechnology companies. He held an individual NIH post-doctoral research fellowship and subsequently an American Heart Association fellowship in the Dept. of Pharmacology of the University of California at San Diego Medical School in the laboratory of Dr. Palmer Taylor. Dr. Herz received his Ph.D. in Physiology and Anatomy from the University of California at Berkeley and a B.A. degree in Biology from the University of California at Santa Barbara. Dr. Herz continued his research serving on the faculty at the Univ. of Texas at Austin while conducting teaching and research before entering the biotechnology industry.
Dr. Herz has received numerous grants and awards for his pharmacological and drug development research. He has authored or co-authored numerous scientific papers, and is an inventor of more than 225 US and international patents, as well as an invited speaker at numerous meetings.
Young-Jun Shin, Ph.D.
Director of Chemistry
Young-Jun Shin received his Ph.D. degree (2001) with Prof. Bruce Lipshutz at University of California, Santa Barbara. After earning his degree, he joined Arena Pharmaceuticals in San Diego. At Arena for 15 years, he made significant contributions to successful CNS and cardiovascular programs spanning early stages of development to late stage clinical trials. He has broad knowledge of ADME, physicochemical, and pharmacological principles with a strong track record of peer-reviewed publications and patents.
As an innovative and hands-on medicinal chemist, his expertise contributed to the development of new compounds for multiple GPCR targets and had a significant impact on organic synthesis, synthetic methodologies, and scale-up synthesis of drug candidates. Recently, his efforts culminated in the successful drug project for the treatment of pulmonary arterial hypertension, and this drug has advanced to Phase 3 clinical trials. After joining Algomedix, he has made important contributions to guiding and advancing medicinal chemistry efforts for TRP targets.
Charles Zuta, Ph.D.
Director of Chemistry, Manufacturing and Control (CMC)
Charles Zuta graduated with a Ph.D. in Food Science and Chemistry from McGill University and has worked in the pharmaceutical industry for over 15 years as a Product Development Scientist and an Analytical Method Development Chemist and has substantial experience in drug development. His expertise spans preclinical and clinical development, including regulatory approval and commercialization.
Charles’ work was instrumental in creating an approved drug product which is currently used during eye surgery to reduce pain, inflammation and inhibit mydriasis. Charles also is an inventor on multiple patents, which include chemical entities under development for neurological indications and is an author of academic publications in peer reviewed journals and conference presentations. Charles has worked on both small and large organic molecule drug products within the Chemistry, Manufacturing and Control Operations (CMC) in the Pharmaceutical Industry, including GLP-regulated facilities.